Depression and SSRIs in a Young Adult

Clinical Scenario

Ella Barnes, 27, a marketing manager, presents via video consultation reporting six months of worsening low mood and anxiety. She has lost interest in activities, is tearful frequently, has poor concentration, disrupted sleep with early morning waking, and has lost weight. She has no psychiatric history and no current suicidal thoughts. She is considering antidepressants but is frightened because a close friend died by suicide shortly after starting fluoxetine.

What This Case Tests

Conducting a thorough depression assessment including PHQ-9 domains; performing a sensitive suicide risk assessment; addressing specific medication fears with evidence-based reassurance; differentiating appropriate SSRI concerns from anxiety-driven avoidance; creating a comprehensive safety-netting plan for SSRI initiation.

Common Mistakes Trainees Make

The three most common mistakes are: dismissing the patient's fear about her friend's suicide as irrational rather than validating it and providing evidence-based context, rushing to prescribe SSRIs without fully exploring symptom severity and preferences, and failing to create a robust monitoring plan for the first weeks of treatment. A fourth error is neglecting psychosocial contributors — workplace stress with redundancies and a strained relationship — which may benefit from non-pharmacological intervention.

The Consultation Challenge

Ella is 27 years old and has been experiencing low mood, anxiety, sleep disturbance, and appetite loss for 6-7 months. Her work performance is declining and her relationship is under strain. This would be a relatively standard depression case — except for one critical detail: her close friend Sophie died by suicide after starting fluoxetine.

This detail transforms the consultation. Ella is terrified of antidepressants because she directly links them to her friend's death. The examiner is testing whether you can address this fear with clinical accuracy and empathy, not dismiss it.

The evidence is nuanced: there is a small increased risk of suicidal thoughts in under-25s when starting SSRIs (MHRA warning), but Ella is 27 and outside this highest-risk age group. However, you cannot simply say "you're 27, so you're fine" — you need to acknowledge her fear, explain the evidence honestly, describe the monitoring protocol, and give her genuine agency in the decision.

Your suicide risk assessment must be thorough but sensitive. Ella is presenting with depression and has a personal connection to suicide — you must ask about suicidal thoughts directly. The examiner needs to see this done well, not avoided out of discomfort.

The management plan should include both pharmacological and non-pharmacological options. Starting an SSRI (sertraline is first-line per NICE) with close monitoring is appropriate, but Ella must feel this is a shared decision. CBT should be offered alongside or as an alternative.

Time check: Spend the first 4 minutes on the depression history and functional impact. Address the friend's death and medication fears by minute 6 — do not avoid this topic. Complete your risk assessment by minute 8. Use the remaining time for a collaborative treatment plan with clear safety netting and follow-up arrangements.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess the quality of your depression history: duration, severity, functional impact across work, relationships, and daily activities. They specifically look for a structured suicide risk assessment — this is non-negotiable given the friend's history. You must ask about suicidal thoughts directly and assess protective factors. Additionally, examiners look for whether you explore the friend's death sensitively, understanding how this experience shapes Ella's health beliefs.

Clinical Management and Medical Complexity: This domain tests your prescribing knowledge under pressure. Examiners expect you to know the MHRA guidance on SSRIs and suicidal ideation in young people, explain it accurately to the patient, and describe the monitoring protocol (weekly review in the first month for under-30s per current NICE guidance). You should offer both medication and psychological therapy, explain realistic timelines for improvement (4-6 weeks), and create a clear safety netting plan. Prescribing without addressing Ella's specific fear, or refusing to prescribe because of the friend's death, both lose marks.

Relating to Others: Examiners watch how you handle the disclosure about Sophie. Do you acknowledge the grief and trauma? Do you validate Ella's fear rather than dismissing it as irrational? Do you use shared decision-making genuinely, giving Ella the information to make her own choice? The consultation should feel like a partnership, not a lecture about SSRIs being safe.

Example Opening

Strong opening: "Hello Ella, thank you for coming in. I can see you've booked in about your mental health. Can you tell me what's been going on?"

Allow Ella to share her story without interruption. When she mentions Sophie: "I'm really sorry about Sophie — that must have been devastating. And I can completely understand why that experience would make you worried about antidepressants. Can you tell me more about what happened?"

This validates her fear and invites her to share rather than shutting the conversation down. It also gives you clinical information about Sophie's case that helps you differentiate it from Ella's situation.

Avoid: "SSRIs are very safe — millions of people take them without any problems." (Dismisses her lived experience and sounds like a pharmaceutical talking point).

How This Appears in the SCA

Depression is one of the most commonly examined topics in the SCA. This case tests your ability to address medication fears with evidence while respecting autonomy. Examiners look for a structured approach: assessment, risk evaluation, shared decision-making, and a clear safety-netting plan.

Key Statistic

Depression affects approximately 1 in 6 adults in England at any given time. SSRIs are effective in 50-65% of moderate-severe depression cases, with sertraline recommended as first-line due to its favourable side-effect profile.

Relevant Guidelines

• NICE CG90/CG91: Depression in adults — recommends SSRIs as first-line pharmacotherapy for moderate-severe depression
• advises increased monitoring in early treatment weeks.

Frequently Asked Questions

How do I handle a patient who is afraid of SSRIs because of a friend's suicide?

First, acknowledge the grief and validate the fear — it is entirely rational given her experience. Then provide accurate, honest information: there is a small increased risk of suicidal thoughts in under-25s in the first weeks of SSRI treatment, which is why close monitoring is essential. Explain that at 27, Ella is outside the highest-risk age group, and that the monitoring protocol (weekly review in the first month) exists specifically to catch early warning signs. Give her genuine choice — she may prefer to start with CBT alone.

Should I still prescribe SSRIs if the patient is reluctant?

Shared decision-making means providing all the information and supporting the patient's choice. If Ella decides she wants to try CBT first without medication, that is a valid and evidence-based choice. If she agrees to try an SSRI, ensure close monitoring is in place. The examiner is assessing your ability to inform and empower, not whether you convince the patient to take medication.

What is the current NICE guidance on monitoring young adults starting SSRIs?

NICE recommends that people under 30 starting SSRIs should be reviewed within one week of first prescribing, and suicidal thinking and self-harm should be monitored weekly for the first month. After the first month, reviews can be less frequent if no concerns arise. This monitoring schedule should be clearly communicated to the patient as a safety measure, not as an indication that the medication is dangerous.

How do I conduct a suicide risk assessment sensitively in this context?

Ask directly but compassionately: "Given everything you've been through with Sophie and how you've been feeling, I need to ask — have you had any thoughts about harming yourself or not wanting to be here?" Direct questions about suicide do not increase risk and are expected by examiners. Assess current ideation, plans, access to means, protective factors, and previous self-harm. Document thoroughly.

What are the first-line SSRI options for young adults with depression?

Sertraline is typically first-line for adults with depression per NICE guidelines, as it has a favourable side effect profile and strong evidence base. Fluoxetine may be avoided in this specific case given the association with Sophie's death, even if clinically appropriate — choosing sertraline demonstrates sensitivity to the patient's concerns while still offering effective treatment.